Evidence map›Paper›PMID 37526791›Full record

ArticleBreast cancer research and treatment2023

The importance of SOCS1 - 1478 CA/del polymorphism and expression in breast cancer: a case-control study in the north of Iran.

Habibbullah Paeiz, Zivar Salehi, Farhad Mashayekhi, Hamid Saeidi Saedi, Laleh Mirzanejad

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Habibbullah PaeizDepartment of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.
Zivar SalehiDepartment of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran. salehiz@guilan.ac.ir.ORCID http://orcid.org/0000-0002-6925-5103
Farhad MashayekhiDepartment of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.
Hamid Saeidi SaediDepartment of Radiation Oncology, Cancer Research Center, Guilan University of Medical Sciences (GUMS), Rasht, Iran.
Laleh MirzanejadDepartment of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis project aimed to evaluate the relationship between the suppressor of cytokine signaling-1 (SOCS1) - 1478 CA > del genetic variation and breast cancer susceptibility. Moreover, we investigated the SOCS1 mRNA expression level in cancerous tissues.

methodsA total of 100 patients with breast cancer and 120 healthy individuals were selected. Genomic DNA was extracted from blood. SOCS1 genotyping and relative gene expression were performed using ARMS-PCR (Amplification-Refractory Mutation System-Polymerase Chain Reaction) and real-time PCR, respectively.

resultsIn breast cancer patients, the prevalence of genotype frequencies of SOCS1 (- 1478 CA > del) CA/CA, CA/del, and del/del was 52, 31, and 17%, respectively. Among controls, the distribution of CA/CA, CA/del, and del/del was 63, 15, and 22%, respectively. The chi-square test reported that a significant difference was observed in the genotypic distribution of SOCS1 (- 1478 CA > del) polymorphism between cases and controls (χ

conclusionIn conclusion, a functional SOCS1 promoter polymorphism (- 1478 CA > del) may affect breast cancer susceptibility.

Indexed as

Breast NeoplasmsCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenotypeHumansIranPolymorphism, GeneticSuppressor of Cytokine Signaling 1 ProteinSOCS1 protein, humanSuppressor of Cytokine Signaling 1 ProteinBreast neoplasmsCytokine signaling-1GenotypeINDEL mutationPolymerase chain reactionPrevalence

Identifiers

PMID37526791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.